Use of Additional Doses of 2024–2025 COVID-19 Vaccine for Adults Aged ≥65 Years and Persons Aged ≥6 Months with Moderate or Severe Immunocompromise: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024
Lauren E. Roper, Monica Godfrey, Ruth Link‐Gelles, Danielle Moulia, Christopher A. Taylor, Georgina Peacock, Noel T. Brewer, Oliver Brooks, George A. Kuchel, H. Keipp Talbot, Robert Schechter, Katherine E. Fleming-Dutra, Lakshmi Panagiotakopoulos
Abstract
This report describes CDCâs recommendation that all people aged â¥65 years and people ages 6 monthsâ64 years with moderate or severe immunocompromise receive a second 2024â2025 COVID-19 vaccine dose 6 months after their last dose.
Topics & Concepts
Coronavirus disease 2019 (COVID-19)Advisory committeeMedicine2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ImmunizationFamily medicineEnvironmental healthVirologyOutbreakImmunologyPolitical scienceDiseaseInternal medicineInfectious disease (medical specialty)Public administrationAntigenSARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyHepatitis B Virus Studies